Loading clinical trials...
Loading clinical trials...
Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day by continuous I...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Genta Incorporated
NCT06678659 · Unresectable, Locally Advanced, and more
NCT00131014 · Non-Hodgkin's Lymphoma, Hodgkin's Disease, and more
NCT03418038 · Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, and more
NCT05735717 · Hematologic Malignancy, Acute Leukemia, and more
NCT06875063 · Non-hodgkin Lymphoma, Refractory Lymphoma, and more
Genta
Berkeley Heights, New Jersey
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions